A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
11/02/2022at 13:15

GN Hearing CEO takes pay cut due to downgrade and launch problems

In 2021, the CEO of GN Hearing, Gitte Aabo, has seen her pay reduced by DKK 1.5m (USD 229,741). R&D letdowns under her watch have resulted in a halving of her annual bonus.
Gitte Aabo, CEO of GN Hearing | Photo: GN Hearing / PR
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

In the year 2021, hearing aid manufacturer GN Hearing was meant to launch two new products. However, a failure from the company’s research and development department delayed the plans, causing both a guidance downgrade to ”around 16 percent” from earlier ”more than 25 percent” and the immediate departure of the man in charge of the team.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: GN Store Nord / PR

    GN Hearing will grow by 5–10 percent in 2022

    For subscribers

  • Gitte Aabo, CEO of GN Hearing | Photo: GN Hearing / PR

    GN chair puts no blame on GN Hearing's CEO Gitte Aabo

    For subscribers

  • Photo: BUNDGAARD CARSTEN/ERH

    Discontent with GN Hearing CEO Gitte Aabo is growing, reports media

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Pr/gn
Hearing health

GN could be potential acquisition target, says bank

Danske Bank’s share price target for GN Group leaves a lot stock potential.

For subscribers

Foto: Philip Davali
Pharma & biotech

Bavarian Nordic breaks even in preliminary financial update

The vaccine maker’s mpox vaccine, Jynneos, has performed so well the last year that Bavarian can now again boast profitability. 

For subscribers

Foto: Gn Hearing / Pr
Hearing health

GN's high expectations deadlocking stock price

Despite shorting positions declining the past month, the hearing company’s equity hasn’t moved an inch in 2023 – perhaps due to conflicting expectations for a yet-to-be-revealed fourth-quarter report.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Principal Laboratory Technologist

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Experienced Patent Counsel

  • Lead Data Architect

  • Application Manager

  • Clinical Operational Associate

  • Head of International Sales

See all jobs

Jobs

  • Principal Laboratory Technologist

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Experienced Patent Counsel

  • Lead Data Architect

  • Application Manager

  • Clinical Operational Associate

  • Head of International Sales

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge